Bangalore, India, January 24, 2018- Navitas
Life Sciences, as a Gold Sponsor, participated at the 11th Indian Society for
Clinical Research (ISCR), annual conference themed “Collaborative Clinical
Research for better Patient outcomes” from 19 – 20 January 2018. The two-day
event, preceded by pre-conference workshops, saw over 800 clinical research
professionals from across the globe deliberate on the collaborative role
required of clinical research stakeholders in a strengthened and improved
clinical research regulatory environment.
Life Sciences, as a Gold Sponsor, participated at the 11th Indian Society for
Clinical Research (ISCR), annual conference themed “Collaborative Clinical
Research for better Patient outcomes” from 19 – 20 January 2018. The two-day
event, preceded by pre-conference workshops, saw over 800 clinical research
professionals from across the globe deliberate on the collaborative role
required of clinical research stakeholders in a strengthened and improved
clinical research regulatory environment.
Speaking at the conference, Ram Yeleswarapu,
President, TAKE Solutions Limited said, “On behalf of the global Navitas Life
Sciences team I would like to thank Indian Society for Clinical Research (ISCR)
for this fantastic opportunity. This is a great experience to be at the
forefront of clinical research development, to hear about the innovations, new
found mechanisms and investments that are happening. As a company, we are truly
proud to be partners at this conference.”
President, TAKE Solutions Limited said, “On behalf of the global Navitas Life
Sciences team I would like to thank Indian Society for Clinical Research (ISCR)
for this fantastic opportunity. This is a great experience to be at the
forefront of clinical research development, to hear about the innovations, new
found mechanisms and investments that are happening. As a company, we are truly
proud to be partners at this conference.”
Navitas Life Sciences helps biopharmaceutical
companies address their most critical problems by bringing together the
capabilities of a full-service CRO, a technology-led life sciences services
provider across clinical, regulatory and safety, and a life sciences big data
services and analytics provider. Navitas Life Sciences has delivered 330+ Phase
II-III Clinical studies and over 400 Non-Interventional Studies across multiple
therapeutic areas including Oncology, Endocrinology, Metabolic, Ophthalmology,
Cardiovascular, Respiratory, Dermatology, Neurology, etc.
companies address their most critical problems by bringing together the
capabilities of a full-service CRO, a technology-led life sciences services
provider across clinical, regulatory and safety, and a life sciences big data
services and analytics provider. Navitas Life Sciences has delivered 330+ Phase
II-III Clinical studies and over 400 Non-Interventional Studies across multiple
therapeutic areas including Oncology, Endocrinology, Metabolic, Ophthalmology,
Cardiovascular, Respiratory, Dermatology, Neurology, etc.
Navitas’ clinical trials capabilities
are augmented by OneClinical, an optimized eClinical and Analytics platform
that offers comprehensive trial oversight. OneClinical ensures faster and
better-informed decision making for successful outcomes. It incorporates
quality by design, delivering effective oversight of trials and provides
actionable insights through comprehensive data visualization.
are augmented by OneClinical, an optimized eClinical and Analytics platform
that offers comprehensive trial oversight. OneClinical ensures faster and
better-informed decision making for successful outcomes. It incorporates
quality by design, delivering effective oversight of trials and provides
actionable insights through comprehensive data visualization.
